NeuroPace Inc
For the period ended Mar 31, 2025. Filed May 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 13, 2025
NPCE$12.69-3.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Cash Flows
| Three Months Ended March 31, | ||
|---|---|---|
| (in thousands) | 2025 | 2024 |
| Cash flows from operating activities | ||
| Net loss | $(6,589) | $(8,925) |
| Adjustments to reconcile net loss to net cash used in operating activities | ||
| Stock-based compensation expense | 2,626 | 2,540 |
| Depreciation | 49 | 45 |
| Amortization of debt discount and issuance costs | 49 | 78 |
| Non-cash interest expense | 213 | 316 |
| PIK interest incurred but not paid on term loan | — | 690 |
| Amortization of right-of-use asset | 413 | 378 |
| Loss (gain) on short-term investments | 82 | (51) |
| Inventory write-downs | 44 | 47 |
| Loss on disposal of property and equipment | 2 | — |
| Changes in operating assets and liabilities | ||
| Accounts receivable | (2,585) | 682 |
| Inventory | (243) | (249) |
| Prepaid expenses and other assets | 150 | 475 |
| Accounts payable | 966 | 950 |
| Accrued liabilities | (2,333) | (3,890) |
| Deferred revenue | 124 | (220) |
| Operating lease liabilities | (450) | (394) |
| Net cash used in operating activities | (7,482) | (7,528) |
| Cash flows from investing activities | ||
| Acquisition of property and equipment | (37) | (104) |
| Proceeds from sale of short-term investments | — | 2,500 |
| Net cash (used in) provided by investing activities | (37) | 2,396 |
| Cash flows from financing activities | ||
| Proceeds from issuance of common stock in follow-on offering, net of underwriting discounts and commissions | 70,265 | — |
| Repurchase of common stock | (49,546) | — |
| Proceeds from issuance of common stock under employee plans | 385 | 721 |
| Taxes withheld and paid related to net share settlement of equity awards | (228) | (649) |
| Proceeds from at-the-market offering, net of sales commission | 232 | — |
| Net cash provided by financing activities | 21,108 | 72 |
| Net increase (decrease) in cash and cash equivalents | 13,589 | (5,060) |
| Cash, cash equivalents and restricted cash | ||
| Beginning of the period | 13,552 | 18,180 |
| End of the period | $27,141 | $13,120 |
| Reconciliation of cash, cash equivalents and restricted cash to balance sheets: | ||
| Cash and cash equivalents | $27,019 | $12,998 |
| Restricted cash | 122 | 122 |
| Cash, cash equivalents and restricted cash in balance sheets | $27,141 | $13,120 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $1,890 | $1,174 |
Condensed Statements of Cash Flows
| Supplemental disclosures of non-cash investing and financing information: | ||
|---|---|---|
| Follow-on offering costs included in accounts payable and accrued liabilities | $611 | $— |
| Deferred offering costs offset against additional paid-in capital | $277 | $— |
| Purchase of property and equipment included in accounts payable | $141 | $55 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.